GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » PEG Ratio

IGMS (IGM Biosciences) PEG Ratio : N/A (As of Mar. 05, 2025)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, IGM Biosciences's PE Ratio without NRI is 0.00. IGM Biosciences's 5-Year EBITDA growth rate is -9.60%. Therefore, IGM Biosciences's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for IGM Biosciences's PEG Ratio or its related term are showing as below:



IGMS's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


IGM Biosciences PEG Ratio Historical Data

The historical data trend for IGM Biosciences's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences PEG Ratio Chart

IGM Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial - - - - -

IGM Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IGM Biosciences's PEG Ratio

For the Biotechnology subindustry, IGM Biosciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGM Biosciences's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's PEG Ratio distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's PEG Ratio falls into.



IGM Biosciences PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

IGM Biosciences's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-9.60
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


IGM Biosciences  (NAS:IGMS) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


IGM Biosciences PEG Ratio Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IGM Biosciences Business Description

Traded in Other Exchanges
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Executives
Steven Weber officer: Principal Accounting Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Lisa Lynn Decker officer: Chief Business Officer C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Misbah Tahir officer: Chief Financial Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto officer: Chief Medical Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Fred Schwarzer director, officer: CEO and President 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt officer: Chief Scientific Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
George Gauthier officer: Chief Commercial Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z. director C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jakob Haldor Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Christina Teng Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803